Axsome Therapeutics to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting

Reuters

昨天

Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting

Axsome Therapeutics Inc. $(AXSM)$, a biopharmaceutical company specializing in central nervous system disorders, announced that data from the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the upcoming 67th Annual Scientific Meeting of the American Headache Society (AHS). The event is scheduled to take place from June 19-22, 2025, in Minneapolis, Minnesota. The presentation will include results from multiple trials, including the INTERCEPT, EMERGE, and MOVEMENT trials, focusing on the efficacy, safety, and long-term effects of SYMBRAVO® in migraine treatment. Key presentations are scheduled for June 19 and June 21, 2025, featuring prominent researchers such as Dr. Richard B. Lipton and Dr. Stewart Tepper.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470587-en) on June 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544979485"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544979485\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544979485?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544979485","market":"fut","top_or_hot":-1,"title":"Axsome Therapeutics to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics Inc. <a href=\"https://laohu8.com/S/AXSM\">$(AXSM)$</a>, a biopharmaceutical company specializing in central nervous system disorders, announced that data from the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the upcoming 67th Annual Scientific Meeting of the American Headache Society (AHS). The event is scheduled to take place from June 19-22, 2025, in Minneapolis, Minnesota. The presentation will include results from multiple trials, including the INTERCEPT, EMERGE, and MOVEMENT trials, focusing on the efficacy, safety, and long-term effects of SYMBRAVO® in migraine treatment. Key presentations are scheduled for June 19 and June 21, 2025, featuring prominent researchers such as Dr. Richard B. Lipton and Dr. Stewart Tepper.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470587-en) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-18 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Axsome Therapeutics Inc. <a href=\"https://laohu8.com/S/AXSM\">$(AXSM)$</a>, a biopharmaceutical company specializing in central nervous system disorders, announced that data from the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the upcoming 67th Annual Scientific Meeting of the American Headache Society (AHS). The event is scheduled to take place from June 19-22, 2025, in Minneapolis, Minnesota. The presentation will include results from multiple trials, including the INTERCEPT, EMERGE, and MOVEMENT trials, focusing on the efficacy, safety, and long-term effects of SYMBRAVO® in migraine treatment. Key presentations are scheduled for June 19 and June 21, 2025, featuring prominent researchers such as Dr. Richard B. Lipton and Dr. Stewart Tepper.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470587-en) on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL1h7vMv:1","article_id":"2544979485","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544979485","pubTimestamp":1750244419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Axsome Therapeutics Inc. , a biopharmaceutical company specializing in central nervous system disorders, announced that data from the SYMBRAVO  clinical program will be presented at the upcoming 67th Annual Scientific Meeting of the American Headache Society . The event is scheduled to take place from June 19-22, 2025, in Minneapolis, Minnesota. The presentation will include results from multiple trials, including the INTERCEPT, EMERGE, and MOVEMENT trials, focusing on the efficacy, safety, and long-term effects of SYMBRAVO in migraine treatment. Key presentations are scheduled for June 19 and June 21, 2025, featuring prominent researchers such as Dr. Richard B. Lipton and Dr. Stewart Tepper.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4505":"高瓴资本持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4007":"制药","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","AXSM":"Axsome Therapeutics, Inc.","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Axsome Therapeutics将展示SYMBRAVO的新发现®第67届美国头痛学会年会临床项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9,"NDAQ":0.9},"content_text":"Axsome Therapeutics to Present New Findings on SYMBRAVO® Clinical Program at 67th Annual American Headache Society Meeting\n    \n\n        Axsome Therapeutics Inc. $(AXSM)$, a biopharmaceutical company specializing in central nervous system disorders, announced that data from the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the upcoming 67th Annual Scientific Meeting of the American Headache Society (AHS). The event is scheduled to take place from June 19-22, 2025, in Minneapolis, Minnesota. The presentation will include results from multiple trials, including the INTERCEPT, EMERGE, and MOVEMENT trials, focusing on the efficacy, safety, and long-term effects of SYMBRAVO® in migraine treatment. Key presentations are scheduled for June 19 and June 21, 2025, featuring prominent researchers such as Dr. Richard B. Lipton and Dr. Stewart Tepper.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470587-en) on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}